PT  - JOURNAL ARTICLE
AU  - Yinon M. Bar-On
AU  - Yair Goldberg
AU  - Micha Mandel
AU  - Omri Bodenheimer
AU  - Ofra Amir
AU  - Laurence Freedman
AU  - Sharon Alroy-Preis
AU  - Nachman Ash
AU  - Amit Huppert
AU  - Ron Milo
TI  - Protection by 4th dose of BNT162b2 against Omicron in Israel
AID  - 10.1101/2022.02.01.22270232
DP  - 2022 Jan 01
TA  - medRxiv
PG  - 2022.02.01.22270232
4099  - http://medrxiv.org/content/early/2022/02/01/2022.02.01.22270232.short
4100  - http://medrxiv.org/content/early/2022/02/01/2022.02.01.22270232.full
AB  - BACKGROUND On January 2, 2022, Israel began administering a fourth dose of BNT162b2 vaccine (Pfizer-BioNTech) to people aged over 60 years and at-risk populations, who had received a third dose of vaccine at least 4 months earlier. The effect of the fourth dose on confirmed coronavirus 2019 disease (Covid-19) and severe illness are still unclear.METHODS We extracted data for the Omicron-dominated period January 15 through January 27, 2022, from the Israeli Ministry of Health database regarding 1,138,681 persons aged over 60 years and eligible for the fourth dose. We compared the rate of confirmed Covid-19 and severe illness between those who had received a fourth dose at least 12 days earlier, those who had received only three doses, and those 3 to 7 days after receiving the fourth dose. We used Poisson regression after adjusting for possible confounding factors.RESULTS The rate of confirmed infection was lower in people 12 or more days after their fourth dose than among those who received only three doses and those 3 to 7 days after vaccination by factors of 2.0 (95% confidence interval [CI], 2.0 to 2.1) and 1.9 (95% CI, 1.8 to 2.0), respectively. The rate of severe illness was lower by factors of 4.3 (95% CI, 2.4 to 7.6) and 4.0 (95% CI, 2.2 to 7.5).CONCLUSIONS Rates of confirmed Covid-19 and severe illness were lower following a fourth dose compared to only three doses.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study did not receive any fundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the Institutional Review Board of the Sheba Medical Center. Helsinki approval number: SMC-8228-21.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe individual-level data used in this study cannot be publicly shared even if anonymized due to privacy restrictions.